4CPS-157 Vedolizumab: early experience and medium-term outcomes in inflammatory bowel disease

BACKGROUND: Vedolizumab is a monoclonal antibody approved for the treatment of moderate to severe inflammatory bowel disease (IBD) for those patients who have had inadequate or loss of response or were intolerant to a tumour necrosis factor alpha inhibitor (anti-TNF-alpha). PURPOSE: To assess prescr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Hosp Pharm
Hlavní autoři: Nieto, L Pedraza, Caballero, R Fernández, Sánchez-Hernández, JG, Rebollo, N, Pérez, MC Piñero, González, D García, Fernández, EM Sáez, López, MJ Otero
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Group 2018
Témata:
Section 4: Clinical pharmacy services
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535236/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.248
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky